Indication
Synovial Sarcoma
32 clinical trials
44 products
6 drugs
Product
PeptiCRAd-1Clinical trial
A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3Status: Recruiting, Estimated PCD: 2025-06-01
Product
PembrolizumabProduct
TazemetostatProduct
Afamitresgene AutoleucelClinical trial
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaStatus: Recruiting, Estimated PCD: 2021-10-10
Clinical trial
A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsStatus: Terminated, Estimated PCD: 2023-12-19
Product
CFT8634Product
CyclophosphamideProduct
OTSA101-DTPA-111InProduct
OTSA101-DTPA-90YClinical trial
Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial SarcomaStatus: Terminated, Estimated PCD: 2024-01-11
Product
MAGE-A4ᶜ¹º³²T cellsClinical trial
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue SarcomaStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
IfosfamideProduct
MASCT-IProduct
DoxorubicinClinical trial
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-27
Clinical trial
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial SarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Afamitresgene autoleucelProduct
AL3818Product
DacarbazineClinical trial
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover StudyStatus: , Estimated PCD: 2025-11-03
Clinical trial
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial SarcomaStatus: Completed, Estimated PCD: 2024-02-26
Product
TP-1287Clinical trial
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-01-10
Product
RamucirumabClinical trial
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial SarcomaStatus: Terminated, Estimated PCD: 2023-02-23
Product
DocetaxelProduct
GemcitabineClinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-31
Product
ItraconazoleProduct
RifampinClinical trial
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced MalignanciesStatus: Completed, Estimated PCD: 2023-04-03
Product
ST316Clinical trial
Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial SarcomaStatus: Completed, Estimated PCD: 2020-01-23
Product
TBI-1301Product
Systemic TreatmentClinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune MicroenvironmentStatus: Terminated, Estimated PCD: 2023-03-04
Product
ItacitinibClinical trial
Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Drug
cyclophosphamideProduct
FludarabineClinical trial
Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)Status: Recruiting, Estimated PCD: 2027-12-31
Product
T cellsProduct
NivolumabClinical trial
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Nanoplexed Poly I:C BO-112Clinical trial
Prospective Phase I/II Trial of an Individualized Peptide Vaccine in Pediatric and AYA Patients With Metastasized Fusion-driven Sarcomas Following Standard TreatmentStatus: Recruiting, Estimated PCD: 2027-06-01
Product
Peptide vaccine IPXClinical trial
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)Status: Active (not recruiting), Estimated PCD: 2019-06-30
Product
PazopanibClinical trial
Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
4-1BBζ EGFR806-EGFRtClinical trial
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)Status: Completed, Estimated PCD: 2021-04-08
Drug
mFOLFOX6Clinical trial
Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NYESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 for Patients With SarcomaStatus: Completed, Estimated PCD: 2022-12-06
Drug
interleukin-2Product
ID-LV305Product
Interferon Gamma-1bClinical trial
Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Synovial Sarcoma and Myxoid/Round Cell LiposarcomaStatus: Recruiting, Estimated PCD: 2026-11-30
Drug
fludarabineProduct
NY-ESO-1 TCR/IL-15 NKClinical trial
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
4-1BBζ B7H3-EGFRt-DHFRProduct
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tGClinical trial
Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)Status: Terminated, Estimated PCD: 2020-02-29
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss TumorsStatus: Terminated, Estimated PCD: 2023-12-04
Product
FHD-609Clinical trial
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma PatientsStatus: Recruiting, Estimated PCD: 2024-01-01
Drug
TrabectedinClinical trial
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-07-17
Product
DexrazoxaneDrug
R-CHOPClinical trial
Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell TumorStatus: Not yet recruiting, Estimated PCD: 2027-10-01
Product
Signifor